Bastien Nguyen

Bastien Nguyen

Auto-generated profile, based on publicly available information

Bastien Nguyen

Eli Lilly and Company, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Cell
Verified
Journal Article
Closed access
BNBastien Nguyen
Bastien Nguyen
CFChristopher Fong
Christopher Fong
ALAnisha Luthra
Anisha Luthra
SSShaleigh A. Smith
Shaleigh A. Smith
RDRenzo G. DiNatale
Renzo G. DiNatale
NSNikolaus Schultz
Nikolaus Schultz

1 September 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
LSLuigi Santoro
Luigi Santoro
Lucia Del MastroLucia Del Mastro
Lucia Del Mastro
BNBastien Nguyen
Bastien Nguyen
LLLuca Livraghi
Luca Livraghi
HAHatem A. Azim
Hatem A. Azim

27 March 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KSKonrad H. Stopsack
Konrad H. Stopsack
SNSubhiksha Nandakumar
Subhiksha Nandakumar
AWAndreas G. Wibmer
Andreas G. Wibmer
SHSamuel Haywood
Samuel Haywood
EWEmily S. Weg
Emily S. Weg
WAWassim Abida
Wassim Abida
Purpose: The genomic underpinning of clinical phenotypes and outcomes in metastatic castration-sensitive prostate cancer is unclear. Experimental Design: In patients with metastatic castration-sensitive prostate cancer at a tertiary referral center, clinical-grade targeted tumor sequencing was performed to quantify tumor DNA copy number alterations and alterations in predefined oncogenic signaling pathways. Disease volume was classified as high volume (≥4 bone metastases or visceral metastases) versus low volume. Results: Among 424 patients (88% white), 213 (50%) had high-volume disease and 211 (50%) had low-volume disease, 275 (65%) had de novo metastatic disease, and 149 (35%) had metastatic recurrence of nonmetastatic disease. Rates of castration resistance [adjusted hazard ratio, 1.84; 95% confidence interval (CI), 1.40–2.41] and death (adjusted hazard ratio, 3.71; 95% CI, 2.28–6.02) were higher in high-volume disease. Tumors from high-volume disease had more copy number alterations. The NOTCH, cell cycle, and epigenetic modifier pathways were the highest-ranking pathways enriched in high-volume disease. De novo metastatic disease differed from metastatic recurrences in the prevalence of CDK12 alterations but had similar prognosis. Rates of castration resistance differed 1.5-fold to 5-fold according to alterations in AR, SPOP (inverse), and TP53, and the cell cycle, WNT (inverse), and MYC pathways, adjusting for disease volume and other genomic pathways. Overall survival rates differed 2-fold to 4-fold according to AR, SPOP (inverse), WNT (inverse), and cell-cycle alterations. PI3K pathway alterations were not associated with prognosis once adjusted for other factors. Conclusions: This study identified genomic features associated with prognosis in metastatic castration-sensitive disease that may aid in molecular classification and treatment selection.

16 June 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ZSZsofia K. Stadler
Zsofia K. Stadler
AMAnna Maio
Anna Maio
DCDebyani Chakravarty
Debyani Chakravarty
YKYelena Kemel
Yelena Kemel
MSMargaret Sheehan
Margaret Sheehan
MRMark E. Robson
Mark E. Robson
PURPOSE: Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer. METHODS: Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype–directed therapy were determined. RESULTS: Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base classification, 9% (n = 1042) had an LP/P variant in a gene with therapeutic implications (4% level 1; 4% level 3B; < 1% level 4). BRCA1/2 variants accounted for 42% of therapeutically actionable findings, followed by CHEK2 (13%), ATM (12%), mismatch repair genes (11%), and PALB2 (5%). When limited to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B genetic findings and 3.2% (n = 289) received germline genotype–directed therapy. Germline genotype–directed therapy was received by 61% and 18% of metastatic cancer patients with level 1 and level 3B findings, respectively, and by 54% of BRCA1/2, 75% of mismatch repair, 43% of PALB2, 35% of RAD51C/D, 24% of BRIP1, and 19% of ATM carriers. Of BRCA1/2 patients receiving a poly(ADP-ribose) polymerase inhibitor, 45% (84 of 188) had tumors other than breast or ovarian cancer, wherein the drug, at time of delivery, was delivered in an investigational setting. CONCLUSION: In a pan-cancer analysis, 8% of patients with advanced cancer harbored a germline variant with therapeutic actionability with 40% of these patients receiving germline genotype–directed treatment. Germline sequence analysis is additive to tumor sequence analysis for therapy selection and should be considered for all patients with advanced cancer.

20 March 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
KKKevin Kalinsky
Kevin Kalinsky
GBGiampaolo Bianchini
Giampaolo Bianchini
EHErika Hamilton
Erika Hamilton
SGStephanie L Graff
Stephanie L Graff
KPKYONG HWA PARK
KYONG HWA PARK
SWSeth Wander
Seth Wander
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein, we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i. METHODS: This double-blind, randomized phase III study enrolled patients with disease progression on previous CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i + ET. Patients were randomly assigned (1:1) to abemaciclib + fulvestrant or placebo + fulvestrant. The primary end point was investigator-assessed progression-free survival (PFS). Secondary end points included PFS by blinded independent central review, objective response rate (ORR), and safety. RESULTS: This study randomly assigned 368 patients (abemaciclib + fulvestrant, n = 182 placebo + fulvestrant, n = 186). At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001). A consistent treatment effect was seen across major clinical and genomic subgroups, including with/without ESR1 or PIK3CA mutations. Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015). No new safety signals were observed, with findings consistent with the known safety profile of abemaciclib. CONCLUSION: Abemaciclib + fulvestrant significantly improved PFS after disease progression on previous CDK4/6i + ET in patients with HR+, HER2– ABC, offering an additional targeted therapy option for these patients.

1 November 2020 in European Urology
Verified
Journal Article
Closed access
BNBastien Nguyen
Bastien Nguyen
JMJose Mauricio Mota
Jose Mauricio Mota
SNSubhiksha Nandakumar
Subhiksha Nandakumar
KSKonrad H. Stopsack
Konrad H. Stopsack
EWEmily Weg
Emily Weg
WAWassim Abida
Wassim Abida